mGluR2/3 agonist LY379268 rescues NMDA and GABAA receptor level deficits induced in a two-hit mouse model of schizophrenia (Q34513221)

2 August 2017

title

mGluR2/3 agonist LY379268 rescues NMDA and GABAA receptor level deficits induced in a two-hit mouse model of schizophrenia (English)

1 reference

Erratum to: mGluR2/3 agonist LY379268 rescues NMDA and GABAA receptor level deficits induced in a two-hit mouse model of schizophrenia.

2 August 2017

1 reference

corrigendum / erratum

0 references

author

Xu-Feng Huang

5

1 reference

2 August 2017

Peta Snikeris

2

0 references

Martin Engel

object named as

Martin Engel

1

0 references

Natalie Matosin

object named as

Natalie Matosin

3

0 references

Kelly A. Newell

object named as

Kelly Anne Newell

4

0 references

author name string

Elisabeth Frank

6

1 reference

2 August 2017

publication date

10 February 2016

1 reference

2 August 2017

1 reference

2 August 2017

volume

233

1 reference

2 August 2017

issue

8

1 reference

2 August 2017

page(s)

1349-1359

1 reference

A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Discovery, validation and characterization of Erbb4 and Nrg1 haplotypes using data from three genome-wide association studies of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Effects of metabotropic glutamate receptor 2/3 agonism and antagonism on schizophrenia-like cognitive deficits induced by phencyclidine in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Differences in the subregional and cellular distribution of GABAA receptor binding in the hippocampal formation of schizophrenic brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Up-regulation of GABAA receptor binding on neurons of the prefrontal cortex in schizophrenic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Subchronic phencyclidine in rats: alterations in locomotor activity, maze performance, and GABA(A) receptor binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Schizophrenia-like GABAergic gene expression deficits in cerebellar Golgi cells from rats chronically exposed to low-dose phencyclidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

The neuregulin signaling pathway and schizophrenia: From genes to synapses and neural circuits

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Medial-frontal cortex hypometabolism in chronic phencyclidine exposed rats assessed by high resolution magic angle spin 11.7 T proton magnetic resonance spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Methamphetamine Use and Schizophrenia: A Population-Based Cohort Study in California

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Effects of the mGlu2/3 receptor agonist LY379268 on motor activity in phencyclidine-sensitized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Increased levels of serotonin 2A receptors and serotonin transporter in the CNS of neuregulin 1 hypomorphic/mutant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Mice mutant for genes associated with schizophrenia: common phenotype or distinct endophenotypes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Multiple metabotropic glutamate receptor subtypes modulate GABAergic neurotransmission in rat periaqueductal grey neurons in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Excitatory and inhibitory neurotransmission is chronically altered following perinatal NMDA receptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Prefrontal GABA(A) receptor alpha-subunit expression in normal postnatal human development and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Phencyclidine-induced Loss of Asymmetric Spine Synapses in Rodent Prefrontal Cortex is Reversed by Acute and Chronic Treatment with Olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Decreased levels of D-aspartate and NMDA in the prefrontal cortex and striatum of patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Density of metabotropic glutamate receptors 2 and 3 (mGluR2/3) in the dorsolateral prefrontal cortex does not differ with schizophrenia diagnosis but decreases with age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Reciprocal signalling between NR2 subunits of the NMDA receptor and neuregulin1 and their role in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

GluN2B protein deficits in the left, but not the right, hippocampus in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Differential expression of metabotropic glutamate receptors 2 and 3 in schizophrenia: a mechanism for antipsychotic drug action?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Identification of a serotonin/glutamate receptor complex implicated in psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Metabotropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Stimulation of the metabotropic glutamate 2/3 receptor attenuates social novelty discrimination deficits induced by neonatal phencyclidine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Stimulation of metabotropic glutamate (mGlu) 2 receptor and blockade of mGlu1 receptor improve social memory impairment elicited by MK-801 in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Involvement of glutamatergic and GABAergic transmission in MK-801-increased gamma band oscillation power in rat cortical electroencephalograms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Effects of the mGluR2/3 agonist LY379268 on ketamine-evoked behaviours and neurochemical changes in the dentate gyrus of the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Losing your inhibition: linking cortical GABAergic interneurons to schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Schizophrenia: a consequence of gene-environment interactions?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Altered motor activity, exploration and anxiety in heterozygous neuregulin 1 mutant mice: implications for understanding schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Phencyclidine affects firing activity of basolateral amygdala neurons related to social behavior in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Neuronal diversity and temporal dynamics: the unity of hippocampal circuit operations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Social interaction deficits caused by chronic phencyclidine administration are reversed by oxytocin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Perspectives on the mGluR2/3 agonists as a therapeutic target for schizophrenia: Still promising or a dead end?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Glutamate receptor subunits are altered in forebrain and cerebellum in rats chronically exposed to the NMDA receptor antagonist phencyclidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Pharmacogenetic analysis of the mGlu2/3 agonist LY2140023 monohydrate in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Distinct neurobehavioural effects of cannabidiol in transmembrane domain neuregulin 1 mutant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Transmembrane domain Nrg1 mutant mice show altered susceptibility to the neurobehavioural actions of repeated THC exposure in adolescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Differential plasma membrane distribution of metabotropic glutamate receptors mGluR1α, mGluR2 and mGluR5, relative to neurotransmitter release sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Metabotropic glutamate receptor mGluR2/3 and mGluR5 binding in the anterior cingulate cortex in psychotic and nonpsychotic depression, bipolar disorder and schizophrenia: implications for novel mGluR-based therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

From Revolution to Evolution: The Glutamate Hypothesis of Schizophrenia and its Implication for Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

GABAergic interneuron origin of schizophrenia pathophysiology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

A neuregulin 1 transmembrane domain mutation causes imbalanced glutamatergic and dopaminergic receptor expression in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Schizophrenia-related endophenotypes in heterozygous neuregulin-1 'knockout' mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

The metabotropic glutamate 2/3 receptor agonist LY379268 counteracted ketamine-and apomorphine-induced performance deficits in the object recognition task, but not object location task, in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Insight into the function of Group I and Group II metabotropic glutamate (mGlu) receptors: behavioural characterization and implications for the treatment of CNS disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Neuregulin 1 and susceptibility to schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Distribution of metabotropic glutamate receptor mGluR3 in the mouse CNS: differential location relative to pre- and postsynaptic sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Dynamic mobility of functional GABAA receptors at inhibitory synapses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Group II metabotropic glutamate receptors modify N-methyl-D-aspartate receptors via Src kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

The role of NMDA receptor upregulation in phencyclidine-induced cortical apoptosis in organotypic culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Synergistic effect of combined treatment with risperidone and galantamine on phencyclidine-induced impairment of latent visuospatial learning and memory: Role of nAChR activation-dependent increase of dopamine D1 receptor-mediated neurotransmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Group II metabotropic glutamate receptor agonist LY379268 regulates AMPA receptor trafficking in prefrontal cortical neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Molecular evidence of N-methyl-D-aspartate receptor hypofunction in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Impact of Cannabis Use on the Development of Psychotic Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Rapid cortico-limbic alterations in AMPA receptor densities after administration of PCP: implications for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

Support for involvement of neuregulin 1 in schizophrenia pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-016-4230-0

The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats

21 January 2018

1 reference

12 December 2020

Distribution of metabotropic glutamate 2 and 3 receptors in the rat forebrain: Implication in emotional responses and central disinhibition

1 reference

12 December 2020

Violence and Severe Mental Illness: The Effects of Substance Abuse and Nonadherence to Medication

1 reference

12 December 2020

Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice

1 reference

12 December 2020

Lack of effect of LY314582 (a group 2 metabotropic glutamate receptor agonist) on phencyclidine-induced locomotor activity in metabotropic glutamate receptor 2 knockout mice

1 reference

12 December 2020

LY-2140023, a prodrug of the group II metabotropic glutamate receptor agonist LY-404039 for the potential treatment of schizophrenia

1 reference

12 December 2020

Synaptic activation of AMPA receptors inhibits GABA release from cerebellar interneurons

1 reference

12 December 2020

Support for involvement of neuregulin 1 in schizophrenia pathophysiology

1 reference

12 December 2020

Assembly of GABAAReceptors Composed of α1 and β2 Subunits in Both Cultured Neurons and Fibroblasts

1 reference

12 December 2020

The environment and susceptibility to schizophrenia

1 reference

12 December 2020

Modulation of hippocampus-prefrontal cortex synaptic transmission and disruption of executive cognitive functions by MK-801.

1 reference

12 December 2020

The preclinical properties of a novel group II metabotropic glutamate receptor agonist LY379268.

1 reference

12 December 2020

Glutamatergic theories of schizophrenia.

1 reference

12 December 2020

Altered dimerization of metabotropic glutamate receptor 3 in schizophrenia

1 reference

12 December 2020

Augmentation of locomotor activity by chronic phencyclidine is associated with an increase in striatal NMDA receptor function and an upregulation of the NR1 receptor subunit

1 reference

12 December 2020

Intracerebral adult stem cells transplantation increases brain-derived neurotrophic factor levels and protects against phencyclidine-induced social deficit in mice

1 reference

12 December 2020

10.1007/S00213-016-4230-0

Identifiers

DOI

1 reference

Dimensions Publication ID

2 August 2017

1016332347

0 references

1 reference